EA201792161A1 - Ингибиторы калликреинов плазмы и их применение для профилактики приступа наследственного ангионевротического отека - Google Patents

Ингибиторы калликреинов плазмы и их применение для профилактики приступа наследственного ангионевротического отека

Info

Publication number
EA201792161A1
EA201792161A1 EA201792161A EA201792161A EA201792161A1 EA 201792161 A1 EA201792161 A1 EA 201792161A1 EA 201792161 A EA201792161 A EA 201792161A EA 201792161 A EA201792161 A EA 201792161A EA 201792161 A1 EA201792161 A1 EA 201792161A1
Authority
EA
Eurasian Patent Office
Prior art keywords
prevention
plasma
callicrein
domestic
inhibitors
Prior art date
Application number
EA201792161A
Other languages
English (en)
Inventor
Юнг Чиунг
Берт Эйделман
Дэниел Дж. Секстон
Original Assignee
Дайэкс Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57005262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201792161(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дайэкс Корп. filed Critical Дайэкс Корп.
Publication of EA201792161A1 publication Critical patent/EA201792161A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к антителам против калликреина плазмы, связывающимся с активным калликреином плазмы, и способам применения таких антител в профилактике приступа наследственного ангионевротического отека или снижении частоты приступов наследственного ангионевротического отека.
EA201792161A 2015-03-30 2016-03-30 Ингибиторы калликреинов плазмы и их применение для профилактики приступа наследственного ангионевротического отека EA201792161A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562140289P 2015-03-30 2015-03-30
US201562140277P 2015-03-30 2015-03-30
US201562214293P 2015-09-04 2015-09-04
PCT/US2016/024921 WO2016160926A1 (en) 2015-03-30 2016-03-30 Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack

Publications (1)

Publication Number Publication Date
EA201792161A1 true EA201792161A1 (ru) 2018-04-30

Family

ID=57005262

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792161A EA201792161A1 (ru) 2015-03-30 2016-03-30 Ингибиторы калликреинов плазмы и их применение для профилактики приступа наследственного ангионевротического отека

Country Status (14)

Country Link
US (2) US20180298110A1 (ru)
EP (2) EP3286226A4 (ru)
JP (3) JP7008920B2 (ru)
KR (2) KR20230164767A (ru)
CN (1) CN107614532A (ru)
AU (2) AU2016243160B2 (ru)
BR (1) BR112017020864A2 (ru)
CA (1) CA2979713A1 (ru)
CO (1) CO2017009404A2 (ru)
EA (1) EA201792161A1 (ru)
HK (1) HK1250995A1 (ru)
IL (2) IL305207A (ru)
MX (2) MX2017012423A (ru)
WO (1) WO2016160926A1 (ru)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
US11299553B2 (en) 2013-03-15 2022-04-12 Takeda Pharmaceutical Company Limited Anti-plasma kallikrein antibodies
US11401346B2 (en) 2011-01-06 2022-08-02 Takeda Pharmaceutical Company Limited Nucleic acids encoding plasma kallikrein binding proteins
US11505620B2 (en) 2010-01-06 2022-11-22 Takeda Pharmaceutical Company Limited Methods of detecting plasma kallikrein
US12084515B2 (en) 2021-06-11 2024-09-10 Takeda Pharmaceutical Company Limited Compositions and methods for treatment of diabetic macular edema

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102424183B1 (ko) 2014-01-21 2022-07-26 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
KR20230109785A (ko) 2014-03-27 2023-07-20 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
EP3513197A1 (en) * 2016-09-16 2019-07-24 Dyax Corp. Metabolite biomarkers for diseases associated with the contact activation system
JP7210540B2 (ja) 2017-08-04 2023-01-23 武田薬品工業株式会社 血漿カリクレインの阻害剤およびその使用
WO2019166572A1 (en) * 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
US20200405708A1 (en) * 2018-02-28 2020-12-31 Attune Pharmaceuticals, Inc. Treatment of hereditary angioedema
CN113056304A (zh) * 2018-08-30 2021-06-29 戴埃克斯有限公司 用于治疗遗传性血管性水肿发作的血浆激肽释放酶抑制剂及其用途
CN114166924A (zh) * 2021-12-03 2022-03-11 中国医学科学院北京协和医院 尿液蛋白标志物在诊断遗传性血管水肿中的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
CA2180950C (en) 1994-01-11 2005-03-29 William Markland Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
EP1941867B1 (en) 2002-06-07 2011-10-12 Dyax Corp. Modified kunitz domain polypeptide
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
HUE057244T2 (hu) * 2010-01-06 2022-04-28 Takeda Pharmaceuticals Co Plazma kallikreint kötõ fehérjék
KR102502293B1 (ko) * 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
RS56429B1 (sr) 2011-05-02 2018-01-31 Millennium Pharm Inc Formulacija za anti- 4 7 antitelo
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
KR102203880B1 (ko) * 2013-01-20 2021-01-15 다이액스 코포레이션 브래디키닌 매개 장애의 평가 및 치료
CN105051068A (zh) * 2013-03-15 2015-11-11 戴埃克斯有限公司 抗血浆激肽释放酶抗体
KR20140119396A (ko) * 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
KR102521947B1 (ko) * 2013-10-21 2023-04-14 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
KR102424183B1 (ko) * 2014-01-21 2022-07-26 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11505620B2 (en) 2010-01-06 2022-11-22 Takeda Pharmaceutical Company Limited Methods of detecting plasma kallikrein
US11401346B2 (en) 2011-01-06 2022-08-02 Takeda Pharmaceutical Company Limited Nucleic acids encoding plasma kallikrein binding proteins
US11299553B2 (en) 2013-03-15 2022-04-12 Takeda Pharmaceutical Company Limited Anti-plasma kallikrein antibodies
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
US12084515B2 (en) 2021-06-11 2024-09-10 Takeda Pharmaceutical Company Limited Compositions and methods for treatment of diabetic macular edema

Also Published As

Publication number Publication date
JP7008920B2 (ja) 2022-01-25
AU2016243160A1 (en) 2017-10-05
BR112017020864A2 (pt) 2018-07-10
JP2023130442A (ja) 2023-09-20
IL254292A0 (en) 2017-10-31
US20220169749A1 (en) 2022-06-02
CO2017009404A2 (es) 2018-03-09
KR20230164767A (ko) 2023-12-04
AU2022203180A1 (en) 2022-06-02
KR102607829B1 (ko) 2023-12-01
MX2023010206A (es) 2023-09-11
CN107614532A (zh) 2018-01-19
AU2016243160B2 (en) 2022-02-24
NZ735659A (en) 2023-08-25
US20180298110A1 (en) 2018-10-18
HK1250995A1 (zh) 2019-01-18
EP3286226A4 (en) 2018-12-05
EP3286226A1 (en) 2018-02-28
JP7309836B2 (ja) 2023-07-18
CA2979713A1 (en) 2016-10-06
EP3916020A1 (en) 2021-12-01
WO2016160926A1 (en) 2016-10-06
MX2017012423A (es) 2018-01-26
JP2022037131A (ja) 2022-03-08
KR20170135885A (ko) 2017-12-08
IL305207A (en) 2023-10-01
JP2018514510A (ja) 2018-06-07

Similar Documents

Publication Publication Date Title
EA201792161A1 (ru) Ингибиторы калликреинов плазмы и их применение для профилактики приступа наследственного ангионевротического отека
EA201691470A1 (ru) Белки, связывающие калликреин плазмы, и их применение для лечения наследственного ангионевротического отека
EA201891532A1 (ru) Композиции и способы лечения гемоглобинопатий
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890161A1 (ru) Терапевтические композиции, комбинации и способы применения
EA201891057A1 (ru) Композиции и способы для ингибирования активности аргиназы
MX2018005292A (es) Inhibidores de acc y usos de los mismos.
EA201890926A1 (ru) ТРИАЗОЛОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
JO3558B1 (ar) تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
EA201692370A1 (ru) КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
EA201591278A1 (ru) Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
IL259691A (en) Plasma kallikrein inhibitors and their uses for the treatment of hereditary angioedema attack
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
BR112018012304A2 (pt) composições e métodos para diminuir expressão de tau
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
EA201991876A1 (ru) Антитела против фактора d и их применения
BR112018014247A2 (pt) inibição de reação alérgica usando um inibidor il-33
MX2018003301A (es) Inhibidores de pcna.
IL281063A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t